Pneumonia in HIV-Infected Patients in the HAART Era: Incidence, Risk, and Impact of the Pneumococcal Vaccination

Journal of Medical Virology

Volumn 72, Issue 4, 2004, Pages 517-524

  Lopez Palomo C ^a   Martin Zamorano M ^a   Benitez E ^a   Fernandez Gutierrez C ^a   Guerrero, F ^a   Rodriguez Iglesias M ^b   Giron Gonzalez J A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

Bacteremia; Highly active antiretroviral therapy; HIV infection; Pneumococcal disease; Pneumonia; Vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CD4 ANTIGEN; CLARITHROMYCIN; COTRIMOXAZOLE; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INCIDENCE; INFECTION RISK; LOBAR PNEUMONIA; LYMPHOCYTE COUNT; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PNEUMONIA; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE ACTIVATION; VACCINATION; VALIDATION PROCESS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY; INCIDENCE; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM-INTRACELLULARE; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 1542304577     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20045     Document Type: Article

References (28)

1. Ahmed F, Steinhoff MC, Rodríguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. 1996. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results of a randomized trial. J Infect Dis 173:83-90.
2. Bartlett JG. 1998. Pneumonia in the patient with HIV infection. Infect Dis Clin North Am 12:807-820.
3. Breiman RF, Keller DW, Phelan MA, Sniadack DH, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold AL. 2000. Evaluation of the effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 160:2633-2638.
4. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. 1996. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA panel. JAMA 276:146-154.
5. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. 1997. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 277:1962-1969.
6. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. 1998. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. JAMA 280:78-86.
7. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. 2000. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. JAMA 283:2936-2937.
8. Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 46(RR-8):1-24.
9. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, Canueto-Quintero J, Sanchez-Porto A, Vergara-Campos A, Marin-Casanova P, Cordoba-Dona JA. 1997. Multivariate analysis of risk factors for infections due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study. Clin Infect Dis 24:1052-1059.
10. Cordero E, Pachón J, Rivero A, Giron JA, Gomez-Mateos J, Merino MD, Torres-Tortosa M, Gonzalez-Serrano M, Aliaga L, Collado A, Hernandez-Quero J, Barrera A, Nuno E. 2000. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. Validation of severity criteria. Am Rev Respir Crit Care Med 162:2063-2068.
11. Cordero E, Pachón J, Rivero A, Giron JA, Gomez-Mateos J, Merino MD, Torres-Tortosa M, Gonzalez-Serrano M, Aliaga L, Collado A, Hernandez-Quero J, Barrera A, Nuno E. 2002. Utility of sputum culture for the diagnosis of bacterial pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis 21:362-367.
12. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE, Adult and Adolescent Spectrum of HIV Disease Project. 2001. Pneumococcal disease among human immunodeficiency virus-infected persons: Incidence, risk factors, and impact of vaccination. Clin Infect Dis 32:794-800.
13. Fedson DS, Chiarello LA. 1983. Previous hospital care and pneumococcal bacteremia: Importance for pneumococcal immunization. Arch Intern Med 143:885-889.
14. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, Whitworth J, Gilks CF. 2000.23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised and placebo controlled trial. Lancet 355:2106-2111.
15. Gebo KA, Moore RD, Kerully JC, Chaisson RE. 1996. Risk factors for pneumococcal disease in human immunodeficiency-virus infected patients. J Infect Dis 173:857-862.
16. Guerrero M, Kruger S, Sayito A, Sorvillo F, Cheng KJ, French C, Beall G. 1999. Pneumonia in HIV-infected patients: A case-control survey of factors involved in risk and prevention. AIDS 13:1971-1975.
17. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Jr., Witt MD, Bozzette SA, McCutchan JA. 1996. Prophylaxis against Mycobacterium avium complex with weekly azithromycin, rifabutin or both. N Engl J Med 335:392-398.
18. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, Rosen MJ, Mangura BT, Hopewell PC. 1995. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 333:845-851.
19. Kroon FP, van Furth R, Bruinsten SM. 1996. The effects of immunization in human immunodeficiency virus type 1 infection. N Engl J Med 335:817-819.
20. Lindenburg CE, Langendam MW, Benthem BH, Miedema F, Coutinho RA. 2001. No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-causes pneumonia. AIDS 15:1315-1317.
21. McNahten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW, the Adult/Adolescent Spectrum of Disease Group. 1999. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 13:1687-1695.
22. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860.
23. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. 1999. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 13:415-418.
24. Pierce AB, Hoy JF. 2001. Is the recommendation for pneumococcal vaccination of HIV patients evidence based? J Clin Virol 22:255-261.
25. Rose DN, Schechter CB, Sacks HS. 1993. Influenza and pneumococcal vaccination of HIV-infected patients: A policy analysis. Am J Med 94:160-168.
26. Santos J, Palacios R, Ruiz J, Gonzalez M, Marquez M. 2002. Comparative trial of the effect of pneumococcal vaccine on viral load and CD4+ lymphocytes in asymptomatic and antiretrovirally naive HIV-infected patients. Eur J Clin Microbiol Infect Dis 21: 488-489.
27. Schuchat A, Broome CV, Hightower A, Costa SJ, Parkin W. 1991. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. JAMA 265:3275-3279.
28. Tacconelli E, Tumbarello M, de Gaetano K, Cauda R, Ortona L. 1998. Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals. Clin Infect Dis 27:901-902.